Skip to main content

Table 1 Frailty criteria

From: First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

a)

Dependency for daily activities due to comorbidities, different to deterioration from cancer.

b)

Previous history of three or more of these comorbidities, even under control because of a correct treatment:

□ Congestive heart failure

□ Other chronic cardiovascular diseases

□ Chronic obstructive pulmonary disease

□ Cerebrovascular disease

□ Peripheral neuropathy

□ Chronic renal failurea

□ Arterial hypertension

□ Diabetes mellitus

□ Systemic vasculitis

□ Severe arthritis

c)

At least one of these geriatric features:

□ Age > 85 years

□ Fecal or urinary incontinence

□ Spontaneous bone fractures

□ Mild or moderate dementia

□ Frequent falls

  1. Patients must be frail and/or not candidates to receive polychemotherapy as defined by the presence of one or more of the three criteria (a, b, c). aHowever creatinine clearance should be > 30 mL/min for regorafenib treatment